Proof-of-principle evaluation of the efficacy of fewer than three doses of a bivalent HPV16/18 vaccineArchived
The findings from Kreimer et al. need to be confirmed by other studies and require longer-term follow-up.
Kreimer AR, Rodriguez AC, Hildesheim A, Herrero R, Porras C, Schiffman M, González P, Solomon D, Jiménez S, Schiller JT, Lowy DR, Quint W, Sherman ME, Schussler J, Wacholder S; for the CVT Vaccine Group. J Natl Cancer Inst. 2011 Sep 9. [Epub ahead of print]
Three-dose regimens for human papillomavirus (HPV) vaccines are expensive and difficult to complete, especially in settings where the need for cervical cancer prevention is greatest. The findings from Kreimer et al. need to be confirmed by other studies and require longer-term follow-up. However, if a one- or two-dose regimen of HPV vaccination does in fact elicit a good and durable immune response, these findings will have a great impact on costs and strategies for HPV vaccination programmes throughout Europe.
World Health Organization recommendations for the influenza virus vaccine composition for the 2020 southern hemisphere season
11 Oct 2019 - On September 2019, WHO has agreed on the recommended composition of the quadrivalent and trivalent influenza vaccines for the southern hemisphere 2020 influenza season.
Extensively drug-resistant gonorrhoea: risk of further dissemination within and across Europe
1 Apr 2019 - ECDC comment on the study 'Detection in the United Kingdom of the Neisseria gonorrhoeae FC428 clone, with ceftriaxone resistance and intermediate resistance to azithromycin, October to December 2018' by Eyre et al. in the Eurosurveillance edition of 7 March 2019.